Compare Enveric Biosciences Inc (ENVB) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while YieldMax NVDA Option Income Strategy ETF trades at $12.58 (market cap $1.45B). The key difference: YieldMax NVDA Option Income Strategy ETF is far larger — about 213.2× Enveric Biosciences Inc's market cap, and YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| ENVB | NVDY | |
|---|---|---|
Market Cap | $6.80M | $1.45B |
Volume | 64,867 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $10.80 | $17.21 |
52-Week Low | $1.27 | $11.58 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
NVDY trades at $12.565, down 3.42% today amid bearish technical signals. The ETF shows consistent weekly dividend distributions but faces structural limitations on upside participation. Recent analyst coverage highlights declining volatility in underlying NVDA shares, reducing option income potential while NAV erosion remains a concern.
Outlook remains cautious as the fund's high distribution yield comes at the cost of long-term capital appreciation. Key risks include capped upside participation and dependency on NVDA volatility. Investors seeking pure NVDA exposure may find direct ownership more attractive for growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
